RNA interference technologies and therapeutics: From basic research to products

BioDrugs

Volumn 23, Issue 5, 2009, Pages 305-332

  López Fraga, Marta ^a   Martínez, Tamara ^a   Jiménez, Ana ^a  

^a Sylentis SAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATELOCOLLAGEN; CHITOSAN; CYCLODEXTRIN; DENDRIMER; GELATIN; MESSENGER RNA; MICRORNA; POLYETHYLENEIMINE; POLYLYSINE;

CONJUGATION; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENE SILENCING; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MISSENSE MUTATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTOZOON; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA INTERFERENCE; RNA TRANSLATION; SINGLE NUCLEOTIDE POLYMORPHISM; TECHNOLOGY;

ANIMALS; BACTERIAL INFECTIONS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNITY, INNATE; LIPIDS; MICRORNAS; MUTATION; PARASITIC DISEASES; PEPTIDES; POLYMERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS DISEASES;

EID: 70349295861     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11318190-000000000-00000     Document Type: Review

References (192)

1. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998 Feb 19; 391 (6669): 806-811 (Pubitemid 28099681)
2. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001 Jan 15; 15 (2): 188-200 (Pubitemid 32107664)
3. Collins RE, Cheng X. Structural domains in RNAi. FEBS Lett 2005 Oct 31; 579 (26): 5841-5849
4. Nykanen A, Haley B, Zamore PD. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 2001 Nov 2; 107 (3): 309-321
5. Liu J, Carmell MA, Rivas FV, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004 Sep 3; 305 (5689): 1437-1441
6. Song JJ, Smith SK, Hannon GJ, et al. Crystal structure of Argonaute and its implications for RISC slicer activity. Science 2004 Sep 3; 305 (5689): 1434-1437
7. Cerutti L, Mian N, Bateman A. Domains in gene silencing and cell differentiation proteins: the novel PAZ domain and redefinition of the Piwi domain. Trends Biochem Sci 2000 Oct; 25 (10): 481-482
8. Rand TA, Petersen S, Du F, et al. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 2005 Nov 18; 123 (4): 621-629
9. Ma JB, Yuan YR, Meister G, et al. Structural basis for 50-end-specific recognition of guideRNAby the A. fulgidus Piwi protein. Nature 2005 Mar 31; 434 (7033): 666-670
10. Orban TI, Izaurralde E. Decay of mRNAs targeted by RISC requires XRN1, the Ski complex, and the exosome. RNA 2005 Apr; 11 (4): 459-469
11. Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002 Sep 20; 297 (5589): 2056-2060
12. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993 Dec 3; 75 (5): 843-854
13. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993 Dec 3; 75 (5): 855-862
14. LeeY,Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003 Sep 25; 425 (6956): 415-419
15. Lund E, Guttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science 2004 Jan 2; 303 (5654): 95-98
16. Hutvagner G, McLachlan J, Pasquinelli AE, et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001 Aug 3; 293 (5531): 834-838
17. Banerjee D, Slack F. Control of developmental timing by small temporal RNAs: a paradigm for RNA-mediated regulation of gene expression. BioEssays 2002 Feb; 24 (2): 119-129
18. Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005 Aug 4; 436 (7051): 740-744
19. LeeY,Hur I, Park SY, et al. The role of PACT in theRNAsilencing pathway. EMBO J 2006 Feb 8; 25 (3): 522-532
20. Kok KH, Ng MH, Ching YP, et al. Human TRBP and PACT directly interact with each other and associate with Dicer to facilitate the production of small interfering RNA. J Biol Chem 2007 Jun 15; 282 (24): 17649-17657
21. Preall JB, Sontheimer EJ. RNAi: RISC gets loaded. Cell 2005 Nov 18; 123 (4): 543-545
22. Jackson RJ, Standart N. How do microRNAs regulate gene expression? Sci STKE 2007 Jan 2; 367 (367): re1
23. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007 Mar; 17 (3): 118-126
24. Liu J, Valencia-Sanchez MA, Hannon GJ, et al. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 2005 Jul; 7 (7): 719-723
25. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004 Apr 23; 304 (5670): 594-596
26. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005 Jan 14; 120 (1): 15-20
27. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002 Apr 19; 296 (5567): 550-553
28. Paddison PJ, Caudy AA, Bernstein E, et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002 Apr 15; 16 (8): 948-958
29. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpinRNApathways. Nature 2006 May 25; 441 (7092): 537-541
30. Giering JC, Grimm D, Storm TA, et al. Expression of shRNA from a tissuespecific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008 Sep; 16 (9): 1630-1636
31. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-264
32. Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Im-munol 2002; 20: 197-216
33. Schlee M, Hornung V, Hartmann G. siRNA and isRNA: two edges of one sword. Mol Ther 2006 Oct; 14 (4): 463-470
34. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005 Mar; 11 (3): 263-270
35. Kim DH, Behlke MA, Rose SD, et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005 Feb; 23 (2): 222-226
36. Sledz CA, Holko M, de Veer MJ, et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003 Sep; 5 (9): 834-839
37. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004 Mar 5; 303 (5663): 1526-1529
38. Judge AD, Sood V, Shaw JR, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005 Apr; 23 (4): 457-462
39. Kim DH, Longo M, Han Y, et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 2004 Mar; 22 (3): 321-325
40. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005 Aug; 23 (8): 1002-1007
41. Judge AD, Bola G, Lee AC, et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006 Mar; 13 (3): 494-505
42. Saxena S, Jonsson ZO, Dutta A. Small RNAs with imperfect match to en-dogenous mRNA repress translation: implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 2003 Nov 7; 278 (45): 44312-44319
43. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003 Jun; 21 (6): 635-637
44. Persengiev SP, Zhu X, Green MR. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 2004 Jan; 10 (1): 12-18
45. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A 2004 Feb 17; 101 (7): 1892-1897
46. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev 2004 Mar 1; 18 (5): 504-511
47. Qiu S, Adema CM, Lane T. A computational study of off-target effects of RNA interference. Nucleic Acids Res 2005; 33 (6): 1834-1847
48. Snove Jr O, Holen T. Many commonly used siRNAs risk off-target activity. Biochem Biophys Res Commun 2004 Jun 18; 319 (1): 256-263
49. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003 Oct 17; 115 (2): 209-216
50. Schwarz DS, Hutvagner G, Du T, et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003 Oct 17; 115 (2): 199-208
51. Reynolds A, Leake D, Boese Q, et al. Rational siRNA design for RNA interference. Nat Biotechnol 2004 Mar; 22 (3): 326-330
52. Fedorov Y, King A, Anderson E, et al. Different delivery methods-different expression profiles. Nat Methods 2005 Apr; 2 (4): 241
53. Lu S, Cullen BR. Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and microRNA biogenesis. J Virol 2004 Dec; 78 (23): 12868-12876
54. An DS, Qin FX, Auyeung VC, et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther 2006 Oct; 14 (4): 494-504
55. McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A 2008 Apr 15; 105 (15): 5868-5873
56. Yi R, Qin Y, Macara IG, et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003 Dec 15; 17 (24): 3011-3016
57. Castanotto D, Sakurai K, Lingeman R, et al. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res 2007; 35 (15): 5154-5164
58. Patzel V, Rutz S, Dietrich I, et al. Design of siRNAs producing unstructured guide-RNAs results in improved RNA interference efficiency. Nat Bio-technol 2005 Nov; 23 (11): 1440-1444
59. Heale BS, Soifer HS, Bowers C, et al. siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res 2005; 33 (3): e30
60. Amarzguioui M, Prydz H. An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun 2004 Apr 16; 316 (4): 1050-1058
61. Dykxhoorn DM, Lieberman J. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. Annu Rev Biomed Eng 2006; 8: 377-402
62. Pei Y, Tuschl T. On the art of identifying effective and specific siRNAs. Nat Methods 2006 Sep; 3 (9): 670-676
63. Martinez J, Patkaniowska A, Urlaub H, et al. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002 Sep 6; 110 (5): 563-574
64. Braasch DA, Jensen S, Liu Y, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003 Jul 8; 42 (26): 7967-7975
65. Braasch DA, Paroo Z, Constantinescu A, et al. Biodistribution of phospho-diester and phosphorothioate siRNA. Bioorg Med Chem Lett 2004 Mar 8; 14 (5): 1139-1143
66. Jeong JH, Mok H, Oh YK, et al. siRNA conjugate delivery systems. Bioconjug Chem 2009 Jan; 20 (1): 5-14
67. Aigner A. Cellular delivery in vivo of siRNA-based therapeutics. Curr Pharm Des 2008; 14 (34): 3603-3619
68. Morris KV, Rossi JJ. Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection. Hum Gene Ther 2006 May; 17 (5): 479-486
69. Singer O, Marr RA, Rockenstein E, et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 2005 Oct; 8 (10): 1343-1349
70. Xia H, Mao Q, Eliason SL, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004 Aug; 10 (8): 816-820
71. Sabbioni S, Callegari E, Manservigi M, et al. Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA. Gene Ther 2007 Mar; 14 (5): 459-464
72. Suckau L, Fechner H, Chemaly E, et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 2009 Mar 10; 119 (9): 1241-1252
73. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999 Oct 7; 401 (6753): 517-518
74. Sinn PL, Burnight ER, Hickey MA, et al. Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. J Virol 2005 Oct; 79 (20): 12818-12827
75. Liu Q, Muruve DA. Molecular basis of the inflammatory response to ade-novirus vectors. Gene Ther 2003 Jun; 10 (11): 935-940
76. Donahue RE, Kessler SW, Bodine D, et al. Helper virus induced T cell lym-phoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992 Oct 1; 176 (4): 1125-1135
77. Thakker DR, Natt F, Husken D, et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci U S A 2004 Dec 7; 101 (49): 17270-17275
78. Bitko V, Musiyenko A, Shulyayeva O, et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005 Jan; 11 (1): 50-55
79. Luo MC, Zhang DQ, Ma SW, et al. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol Pain 2005; 1: 29
80. Bitko V, Barik S. Respiratory viral diseases: access to RNA interference therapy. Drug Discov Today Ther Strateg 2007; 4 (4): 273-276
81. Nonobe NI, Kachi S, Kondo M, et al. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina 2009 May; 29 (5): 579-585
82. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003 May 30; 9: 210-216
83. Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovasculariza-tion. Retina 2004 Aug; 24 (4): 660 (Pubitemid 39079909)
84. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endo-genous gene by systemic administration of modified siRNAs. Nature 2004 Nov 11; 432 (7014): 173-178
85. Lorenz C, Hadwiger P, John M, et al. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004 Oct 4; 14 (19): 4975-4977
86. Cheng K, Ye Z, Guntaka RV, et al. Enhanced hepatic uptake and bioactivity of type alpha1(I) collagen gene promoter-specific triplex-forming oligonu-cleotides after conjugation with cholesterol. J Pharmacol Exp Ther 2006 May; 317 (2): 797-805
87. Nishina K, Unno T, Uno Y, et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther 2008 Apr; 16 (4): 734-740
88. De Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconjuga-tion for enhanced siRNA delivery and targeting. RNA 2007 Apr; 13 (4): 431-456
89. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 1998 Feb; 8 (2): 84-87
90. Pooga M, Hallbrink M, Zorko M, et al. Cell penetration by transportan. FASEB J 1998 Jan; 12 (1): 67-77
91. Soomets U, Lindgren M, Gallet X, et al. Deletion analogues of transportan. Biochim Biophys Acta 2000 Jul 31; 1467 (1): 165-176
92. Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001 Feb 23; 276 (8): 5836-5840
93. Oehlke J, Scheller A, Wiesner B, et al. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim Biophys Acta 1998 Nov 11; 1414 (1-2): 127-139
94. Morris JC, Bergert ER, Bryant WP. Binding of immunoglobulin G from patients with autoimmune thyroid disease to rat sodium-iodide symporter peptides: evidence for the iodide transporter as an autoantigen. Thyroid 1997 Aug; 7 (4): 527-534
95. Deshayes S, Plenat T, Aldrian-Herrada G, et al. Primary amphipathic cell-penetrating peptides: structural requirements and interactions with model membranes. Biochemistry 2004 Jun 22; 43 (24): 7698-7706
96. Simeoni F, Morris MC, Heitz F, et al. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003 Jun 1; 31 (11): 2717-2724
97. Davidson TJ, Harel S, Arboleda VA, et al. Highly efficient small interfering RNA delivery to primary mammalian neurons induces microRNA-like effects before mRNA degradation. J Neurosci 2004 Nov 10; 24 (45): 10040-10046
98. Kim SH, Jeong JH, Lee SH, et al. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release 2006 Nov 28; 116 (2): 123-129
99. Spagnou S, Miller AD, Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 2004 Oct 26; 43 (42): 13348-13356
100. Zhang C, Tang N, Liu X, et al. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release 2006 May 15; 112 (2): 229-239
101. Santel A, Aleku M, Keil O, et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther 2006 Sep; 13 (18): 1360-1370
102. Vorhies JS, Nemunaitis JJ. Synthetic vs. natural/biodegradable polymers for delivery of shRNA-based cancer therapies. Methods Mol Biol 2009; 480: 11-29
103. Kukowska-Latallo JF, Candido KA, Cao Z, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005 Jun 15; 65 (12): 5317-5324
104. Hussain M, Shchepinov M, Sohail M, et al. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. J Control Release 2004 Sep 14; 99 (1): 139-155
105. Santhakumaran LM, Thomas T, Thomas TJ. Enhanced cellular uptake of a triplex-forming oligonucleotide by nanoparticle formation in the presence of polypropylenimine dendrimers. Nucleic Acids Res 2004; 32 (7): 2102-2112
106. Shukla AA, Hubbard B, Tressel T, et al. Downstream processing of mono-clonal antibodies: application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci 2007 Mar 15; 848 (1): 28-39
107. Kang H, DeLong R, Fisher MH, et al. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res 2005 Dec; 22 (12): 2099-2106 (Pubitemid 41821589)
108. Urban-Klein B, Werth S, Abuharbeid S, et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005 Mar; 12 (5): 461-466
109. Grzelinski M, Urban-Klein B, Martens T, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xeno-grafts. Hum Gene Ther 2006 Jul; 17 (7): 751-766
110. Kim HA, Lee BW, Kang D, et al. Delivery of hypoxia-inducible VEGF gene to rat islets using polyethylenimine. J Drug Target 2009 Jan; 17 (1): 1-9
111. Jiang J, Xia XB, Xu HZ, et al. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J Cell Physiol 2009 Jan; 218 (1): 66-74
112. Ochiya T, Takahama Y, Nagahara S, et al. New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med 1999 Jun; 5 (6): 707-710
113. Takei Y, Kadomatsu K, Yuzawa Y, et al. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004 May 15; 64 (10): 3365-3370
114. Iwaki K, Shibata K, Ohta M, et al. A small interfering RNA targeting pro-teinase-activated receptor-2 is effective in suppression of tumor growth in a Panc1 xenograft model. Int J Cancer 2008 Feb 1; 122 (3): 658-663
115. Kushibiki T, Tomoshige R, Iwanaga K, et al. In vitro transfection of plasmid DNA by cationized gelatin prepared from different amine compounds. J Biomater Sci Polym Ed 2006; 17 (6): 645-658 (Pubitemid 44069699)
116. Howard KA, Rahbek UL, Liu X, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 2006 Oct; 14 (4): 476-484
117. Tan WB, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007 Mar; 28 (8): 1565-1571
118. Hu-Lieskovan S, Heidel JD, BartlettDW, et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005 Oct 1; 65 (19): 8984-8992
119. Bartlett DW, Su H, Hildebrandt IJ, et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 2007 Sep 25; 104 (39): 15549-15554
120. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009 May-Jun; 6 (3): 659-668
121. Wullner U, Neef I, Tur MK, et al. Targeted delivery of short interfering RNAs: strategies for in vivo delivery. Recent Pat Anticancer Drug Discov 2009 Jan; 4 (1): 1-8
122. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004; 32 (19): e149
123. Kim SH, Mok H, Jeong JH, et al. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug Chem 2006 Jan-Feb; 17 (1): 241-244
124. Ikeda S, Ishino S, Harada T, et al. Ligand-free platinum nanoparticles encapsulated in a hollow porous carbon shell as a highly active heterogeneous hydrogenation catalyst. Angew Chem Int Ed Engl 2006 Oct 27; 45 (42): 7063-7066
125. Iinuma H, Maruyama K, Okinaga K, et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 2002 May 1; 99 (1): 130-137
126. McNamara II JO, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006 Aug; 24 (8): 1005-1015
127. Bitko V, Barik S. Phenotypic silencing of cytoplasmic genes using sequencespecific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol 2001; 1: 34
128. Dave RS, Pomerantz RJ. Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains. J Virol 2004 Dec; 78 (24): 13687-13696
129. Wilson JA, Jayasena S, Khvorova A, et al. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci U S A 2003 Mar 4; 100 (5): 2783-2788
130. Zhang Y, Li T, Fu L, et al. Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference. FEBS Lett 2004 Feb 27; 560 (1-3): 141-146
131. Qin XF, An DS, Chen IS, et al. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 2003 Jan 7; 100 (1): 183-188
132. Akkina R, Banerjea A, Bai J, et al. siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Anticancer Res 2003 May-Jun; 23 (3A): 1997-2005
133. Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007 Dec; 117 (12): 3633-3641
134. Hoofnagle JH, Lau D. New therapies for chronic hepatitis B. J Viral Hepat 1997; 4 Suppl. 1: 41-50
135. Randall G, Rice CM. Interfering with hepatitis C virus RNA replication. Virus Res 2004 Jun 1; 102 (1): 19-25
136. Giladi H, Ketzinel-Gilad M, Rivkin L, et al. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003 Nov; 8 (5): 769-776
137. Ge Q, Eisen HN, Chen J. Use of siRNAs to prevent and treat influenza virus infection. Virus Res 2004 Jun 1; 102 (1): 37-42
138. Monick MM, Cameron K, Staber J, et al. Activation of the epidermal growth factor receptor by respiratory syncytial virus results in increased inflammation and delayed apoptosis. J Biol Chem 2005 Jan 21; 280 (3): 2147-2158
139. Kong X, Zhang W, Lockey RF, et al. Respiratory syncytial virus infection in sarcoma. Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet Vaccines Ther 2007; 5: 4
140. Butz K, Ristriani T, Hengstermann A, et al. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003 Sep 4; 22 (38): 5938-5945
141. Wang Z, Ren L, Zhao X, et al. Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J Virol 2004 Jul; 78 (14): 7523-7527
142. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003 Apr 4; 327 (4): 761-766 (Pubitemid 36315917)
143. Zaas DW, Duncan MJ, Li G, et al. Pseudomonas invasion of type I pneu-mocytes is dependent on the expression and phosphorylation of caveolin-2. J Biol Chem 2005 Feb 11; 280 (6): 4864-4872
144. Harth G, Zamecnik PC, Tang JY, et al. Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/ glutamine cell wall structure, and bacterial replication. Proc Natl Acad Sci U S A 2000 Jan 4; 97 (1): 418-423
145. Koo IC, Ohol YM, Wu P, et al. Role for lysosomal enzyme beta-hexos-aminidase in the control of Mycobacteria infection. Proc Natl Acad Sci U S A 2008 Jan 15; 105 (2): 710-715
146. Ngo H, Tschudi C, Gull K, et al. Double-stranded RNA induces mRNA degradation in Trypanosoma brucei. Proc Natl Acad Sci U S A 1998 Dec 8; 95 (25): 14687-14692
147. Djikeng A, Shen S, Tschudi C, et al. Analysis of gene function in Trypanosoma brucei using RNA interference. Methods Mol Biol 2004; 270: 287-298
148. Tschudi C, Djikeng A, Shi H, et al. In vivo analysis of the RNA interference mechanism in Trypanosoma brucei. Methods 2003 Aug; 30 (4): 304-312
149. Inoue N, Otsu K, Ferraro DM, et al. Tetracycline-regulated RNA interference in Trypanosoma congolense. Mol Biochem Parasitol 2002 Apr 9; 120 (2): 309-313
150. Malaney P, Spielman A, Sachs J. The malaria gap. Am J Trop Med Hyg 2004 Aug; 71 (2 Suppl.): 141-146
151. Verdrager J. Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Southeast Asian J Trop Med Public Health 1995 Mar; 26 (1): 23-28
152. Kumar R, Adams B, Oldenburg A, et al. Characterisation and expression of a PP1 serine/threonine protein phosphatase (PfPP1) from the malaria parasite, Plasmodium falciparum: demonstration of its essential role using RNA interference. Malar J 2002 Apr 26; 1: 5
153. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 2005 Aug; 107 (2): 222-239
154. Vayssie L, Vargas M, Weber C, et al. Double-stranded RNA mediates homology-dependent gene silencing of gamma-tubulin in the human parasite Entamoeba histolytica. Mol Biochem Parasitol 2004 Nov; 138 (1): 21-28
155. Martin SE, Caplen NJ. Applications of RNA interference in mammalian systems. Annu Rev Genomics Hum Genet 2007; 8: 81-108
156. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002 Apr; 3 (4): 285-298
157. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 2007 Oct; 8 (10): 749-761
158. Disset A, Bourgeois CF, Benmalek N, et al. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements. Hum Mol Genet 2006 Mar 15; 15 (6): 999-1013
159. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009 Feb 20; 136 (4): 777-793
160. Lu QL, Rabinowitz A, Chen YC, et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 2005 Jan 4; 102 (1): 198-203
161. Wu B, Li Y, Morcos PA, et al. Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 2009 May; 17 (5): 864-871
162. Miller VM, Gouvion CM, Davidson BL, et al. Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res 2004; 32 (2): 661-668
163. Ohnishi Y, Tamura Y, Yoshida M, et al. Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. PLoS ONE 2008; 3 (5): e2248
164. Liang Z, Liu F, Iqbal K, et al. Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. J Alzheimers Dis 2008 Apr; 13 (3): 295-302
165. Miller VM, Xia H, Marrs GL, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A 2003 Jun 10; 100 (12): 7195-7200
166. Koutsilieri E, Rethwilm A, Scheller C. The therapeutic potential of siRNA in gene therapy of neurodegenerative disorders. J Neural Transm Suppl 2007; (72): 43-49
167. Shen TJ, Rogers H, Yu X, et al. Modification of globin gene expression by RNA targeting strategies. Exp Hematol 2007 Aug; 35 (8): 1209-1218
168. Cleary ML. Oncogenic conversion of transcription factors by chromosomal translocations. Cell 1991 Aug 23; 66 (4): 619-622
169. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001 Sep 10; 20 (40): 5695-5707
170. Zucman J,Delattre O, DesmazeC, et al.EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 1993 Aug; 4 (4): 341-345
171. Antonescu CR, Gerald WL, MagidMS, et al. Molecular variants of the EWSWT1 gene fusion in desmoplastic small round cell tumor. Diagn Mol Pathol 1998 Feb; 7 (1): 24-28
172. Panagopoulos I, HoglundM,Mertens F, et al. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 1996 Feb 1; 12 (3): 489-494
173. Chansky HA, Barahmand-Pour F, Mei Q, et al. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J Orthop Res 2004 Jul; 22 (4): 910-917
174. Toub N, Bertrand JR, Tamaddon A, et al. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res 2006 May; 23 (5): 892-900
175. Ying SY, Lin SL. Intron-derived microRNAs: fine tuning of gene functions. Gene 2004 Nov 10; 342 (1): 25-28
176. Griffiths-Jones S. The microRNA registry. Nucleic Acids Res 2004 Jan 1; 32: D109-111
177. Yang M, Mattes J. Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol Ther 2008 Jan; 117 (1): 94-104
178. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs' 179.
179. Davis S,Lollo B,Freier S,et al: Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res, 2006, 34,(8):2294-2304
180. Niepmann M. Activation of hepatitis C virus translation by a liver-specific microRNA. Cell Cycle 2009 May 15; 8 (10): 1473-1477
181. Bertrand JR, Pottier M, Vekris A, et al. Comparison of antisense oligo-nucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res disease Commun 2002 Aug 30; 296 (4): 1000-1004
182. Scholz M, Doerr HW, Cinatl J. Human cytomegalovirus retinitis: patho-genicity, immune evasion and persistence. Trends Microbiol 2003 Apr; 11 (4): 171-178
183. Detrick B, Nagineni CN, Grillone LR, et al. Inhibition of human cytome-galovirus replication in a human retinal epithelial cell model by antisense oligonucleotides. Invest Ophthalmol Vis Sci 2001 Jan; 42 (1): 163-169
184. Geary RS, Henry SP, Grillone LR. Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet 2002; 41 (4): 255-260
185. Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus reti-nitis in patients with AIDS. Am J Ophthalmol 2002 Apr; 133 (4): 467-474
186. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008 Apr 3; 452 (7187): 591-597
187. DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety,
188. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007 Dec; 117 (12): 3623-3632
189. Levin AA, Henry S. Toxicology of oligonucleotide therapeutics and understanding the relevance of the toxicities. In: Cavagnaro JA, editor. Pre-clinical safety evaluation of biopharmaceuticals: a science-based approach to facilitating clinical trials. Hoboken (NJ): John Wiley & Sons, Inc., 2008: 537-575
190. Black LE, Degeorge JJ, Cavagnaro JA, et al. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs. Antisense Res Dev 1993 Winter; 3 (4): 399-404
191. Black LE, Farrelly JG, Cavagnaro JA, et al. Regulatory considerations for sarcoma cells oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies. Antisense Res Dev 1994 Winter; 4 (4): 299-301
192. Capaldi D, Scozzari AN. Manufacturing and analytical processes. In: Crooke ST, editor. Antisense drug technology. 2nd ed. New York: Dekker, 2007